EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC 4.0

Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens

Mohammed Al Musawa iD, Callan R Bleick iD, Shelbye R Herbin iD, Kaylee E Caniff iD, Sean R Van Helden iD, Michael J Rybak iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024-12 · 44 (12) · 927-938

DOI: 10.1002/phar.4629 ↗

At a glance

Übersichtsarbeit in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, published online on 2024-11-27. Written by Mohammed Al Musawa and 5 co-authors. Institution: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Major MEDLINE topics: Anti-Bacterial Agents, Azabicyclo Compounds, Aztreonam, Drug Resistance, Multiple, Bacterial. Cited 68 times so far (Crossref); 63 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Antimicrobial resistance poses a significant public health challenge, particularly with the rise of gram‐negative hospital‐acquired infections resistant to carbapenems. Aztreonam–avibactam (ATM–AVI) is a promising new combination therapy designed to combat multidrug‐resistant (MDR) gram‐negative bacteria, including those producing metallo‐β‐lactamases (MBLs). Aztreonam, a monobactam antibiotic, is resistant to hydrolysis by MBLs but can be degraded by other β‐lactamases. Avibactam, a novel non‐β‐lactam β‐lactamase inhibitor, effectively neutralizes extended‐spectrum β‐lactamases (ESBLs) and AmpC β‐lactamases, restoring aztreonam's efficacy against resistant pathogens. This review covers the chemistry, mechanisms of action, spectrum of activity, pharmacokinetics, pharmacodynamics, and clinical efficacy of ATM–AVI. ATM–AVI combination has shown efficacy against a wide range of resistant Enterobacterales and other gram‐negative bacteria in both in vitro and clinical studies. Pharmacokinetic and pharmacodynamic analyses demonstrate that ATM–AVI maintains effective drug concentrations in the body, with dose adjustments recommended for patients with renal impairment. Clinical trials, including the REVISIT and ASSEMBLE studies, have demonstrated the safety and efficacy of ATM–AVI in treating complicated intra‐abdominal infections (cIAI), urinary tract infections (UTIs), and hospital‐acquired pneumonia (HAP) caused by MDR gram‐negative pathogens. The European Medicines Agency (EMA) has approved ATM–AVI for these indications, and further research is ongoing to optimize dosing regimens and expand its clinical use. This combination represents a critical advancement in the fight against antimicrobial resistance, offering a new therapeutic option for treating severe infections caused by MDR gram‐negative, including MBL‐producing, bacteria.

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamDrug Resistance, Multiple, BacterialGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansbeta-Lactamase InhibitorsDrug Combinations

Author keywords

Enterobacteralesantimicrobial resistanceavibactamaztreonamcarbapenemasegram‐negative bacteriametallo‐β‐lactamasemonobactam

Substances

Anti-Bacterial AgentsavibactamAzabicyclo CompoundsAztreonambeta-Lactamase InhibitorsDrug Combinations

Authors and institutions

  • Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
  • John D. Dingell VA Medical Center, Detroit, Michigan, USA.
  • Department of Pharmacy Services, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA.
  • Division of Infectious Diseases, School of Medicine, Wayne State University, Detroit, Michigan, USA.

ORCID profiles: Mohammed Al Musawa, Callan R Bleick, Shelbye R Herbin, Kaylee E Caniff, Sean R Van Helden, Michael J Rybak

Cite

APA

Al Musawa, M., Bleick, C. R., Herbin, S. R., Caniff, K. E., Van Helden, S. R., & Rybak, M. J. (2024). Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 44(12), 927-938. https://doi.org/10.1002/phar.4629

Vancouver

Al Musawa M, Bleick CR, Herbin SR, Caniff KE, Van Helden SR, Rybak MJ. Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024;44(12):927-938. doi:10.1002/phar.4629

BibTeX
@article{AlMusawa2024,
  author = {Al Musawa, Mohammed and Bleick, Callan R and Herbin, Shelbye R and Caniff, Kaylee E and Van Helden, Sean R and Rybak, Michael J},
  title = {Aztreonam–avibactam: The dynamic duo against multidrug‐resistant gram‐negative pathogens},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  volume = {44},
  number = {12},
  pages = {927--938},
  doi = {10.1002/phar.4629}
}
Start for free →